Gene edit­ing los­es its siz­zle. CRISPR Ther­a­peu­tics IPO de­buts be­neath the range

Some of the bloom has come off the rose of gene edit­ing. CRISPR Ther­a­peu­tics had to ac­cept $14 a share to launch its IPO, a bit be­low the range that it had set for it­self. And that had to be a dis­ap­point­ing de­but af­ter ri­vals Ed­i­tas and In­tel­lia were both able to fire off hot of­fer­ings ear­li­er in the year — though they have al­so been feel­ing the chill more re­cent­ly.

CRISPR Ther­a­peu­tics $CR­SP still came away with $56 mil­lion from the maid­en of­fer­ing, adding $35 mil­lion with a sale of 2.5 mil­lion shares to its big part­ner Bay­er un­der their ear­li­er pact. Add it up and the $91 mil­lion does drop in­to the same ball­park as the $94.4 mil­lion score by Ed­i­tas and the $108 mil­lion reaped by In­tel­lia in the spring. But it’s sig­nif­i­cant­ly less than what the biotech was an­gling for.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.